Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,970,964
  • Shares Outstanding, K 199,014
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,515 M
  • EBITDA $ 1,608 M
  • 60-Month Beta 0.84
  • Price/Sales 3.57
  • Price/Cash Flow 14.93
  • Price/Book 3.51

Options Overview Details

View History
  • Implied Volatility 40.61% (-1.25%)
  • Historical Volatility 19.92%
  • IV Percentile 72%
  • IV Rank 39.43%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 17) 5.03 (5.57%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 94
  • Volume Avg (30-Day) 343
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 10,835
  • Open Int (30-Day) 15,101
  • Expected Range 85.30 to 95.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.22
  • Number of Estimates 7
  • High Estimate 1.57
  • Low Estimate 1.03
  • Prior Year 0.89
  • Growth Rate Est. (year over year) +37.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.25 +1.21%
on 03/24/26
101.00 -10.56%
on 03/02/26
-10.94 (-10.80%)
since 02/27/26
3-Month
89.25 +1.21%
on 03/24/26
112.29 -19.56%
on 01/07/26
-9.78 (-9.77%)
since 12/26/25
52-Week
53.56 +68.65%
on 04/09/25
112.29 -19.56%
on 01/07/26
+29.73 (+49.06%)
since 03/28/25

Most Recent Stories

More News
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

INCY : 90.33 (+0.03%)
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). ...

INCY : 90.33 (+0.03%)
Incyte Announces Executive Leadership Appointments

Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been...

INCY : 90.33 (+0.03%)
2 Growth Stocks with Explosive Upside and 1 We Avoid

2 Growth Stocks with Explosive Upside and 1 We Avoid

AAON : 78.22 (-4.00%)
INCY : 90.33 (+0.03%)
OLLI : 90.34 (+1.23%)
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib...

INCY : 90.33 (+0.03%)
Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

ALNY : 316.09 (-0.40%)
INCY : 90.33 (+0.03%)
$DOWI : 45,216.14 (unch)
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United...

GUD.TO : 7.30 (+1.39%)
INCY : 90.33 (+0.03%)
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio...

GUD.TO : 7.30 (+1.39%)
INCY : 90.33 (+0.03%)
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds

1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds

FIHL : 19.18 (+2.29%)
INCY : 90.33 (+0.03%)
OKTA : 75.47 (+3.06%)
2 Value Stocks to Consider Right Now and 1 We Ignore

2 Value Stocks to Consider Right Now and 1 We Ignore

INCY : 90.33 (+0.03%)
NMIH : 37.45 (+1.60%)
BAND : 17.24 (+2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 92.92
2nd Resistance Point 92.31
1st Resistance Point 91.32
Last Price 90.33
1st Support Level 89.71
2nd Support Level 89.10
3rd Support Level 88.11

See More

52-Week High 112.29
Last Price 90.33
Fibonacci 61.8% 89.86
Fibonacci 50% 82.93
Fibonacci 38.2% 75.99
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.